CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Operating Expenses:
Research and development	$ 187,786	$ 71,028	$ 263,426	$ 316,226
General and administrative	346,222	73,270	589,127	1,303,182
Total Operating Expenses	534,008	144,298	852,553	1,619,408
Operating Loss	(534,008)	(144,298)	(852,553)	(1,619,408)
Other Income/(Expense):
Interest expense	(186,463)	(106,855)	(429,971)	(306,768)
Changes in fair value of contingent purchase consideration	(49,537,836)		(49,537,836)
Impairment of goodwill			(14,335,822)
Change in fair value of derivative liabilities (Note 8)	1,034,991	1,169,514	709,917	1,065,880
Net (Loss)	(49,223,316)	918,361	(64,446,265)	(860,293)
Net (loss) attributable to noncontrolling interests	(7,132,015)		(7,159,298)
Net (Loss) Available to Common Stockholders	$ (42,091,301)	$ 918,361	$ (57,286,967)	$ (860,293)
Net (Loss) Per Common Share - Basic and Diluted	$ (39.85)	$ 1.02	$ (59.67)	$ (0.99)
Shares Used to Compute (Loss) per Share - basic	1,056,343	900,057	960,054	873,309
Shares Used to Compute (Loss) per Share - diluted	1,056,343	900,133	960,054	873,309
Other Comprehensive Income
Net (Loss)	$ (42,091,301)	$ 918,361	$ (57,286,967)	$ (860,293)
Change in foreign currency translation adjustments	5,560	(15,695)	14,073	(20,782)
Comprehensive Income (Loss) and Comprehensive Income (Loss) Available to Common Stockholders	$ (42,085,741)	$ 902,666	$ (57,272,894)	$ (881,075)